LAVA Therapeutics N.V. (LVTX) DCF Valuation
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
LAVA Therapeutics N.V. (LVTX) Bundle
Looking to assess the intrinsic value of LAVA Therapeutics N.V.? Our LVTX DCF Calculator integrates real-world data with comprehensive customization features, enabling you to adjust forecasts and enhance your investment strategies.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | 3.9 | 5.6 | 20.2 | 7.1 | 8.4 | 10.1 | 12.0 | 14.4 | 17.1 |
Revenue Growth, % | 0 | 0 | 42.78 | 262.45 | -65.09 | 19.42 | 19.42 | 19.42 | 19.42 | 19.42 |
EBITDA | -9.9 | -15.3 | -42.8 | -32.2 | -42.2 | -5.1 | -6.0 | -7.2 | -8.6 | -10.3 |
EBITDA, % | 100 | -391.04 | -766.64 | -159.23 | -597.09 | -60 | -60 | -60 | -60 | -60 |
Depreciation | .1 | .2 | .3 | .5 | 1.3 | 2.2 | 2.7 | 3.2 | 3.8 | 4.6 |
Depreciation, % | 100 | 5.68 | 6.19 | 2.6 | 18.88 | 26.67 | 26.67 | 26.67 | 26.67 | 26.67 |
EBIT | -10.0 | -15.5 | -43.1 | -32.7 | -43.5 | -5.1 | -6.0 | -7.2 | -8.6 | -10.3 |
EBIT, % | 100 | -396.72 | -772.82 | -161.83 | -615.97 | -60 | -60 | -60 | -60 | -60 |
Total Cash | 8.7 | 20.3 | 157.5 | 138.6 | 99.7 | 8.4 | 10.1 | 12.0 | 14.4 | 17.1 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .2 | 1.5 | .8 | 3.4 | 1.8 | 3.3 | 3.9 | 4.7 | 5.6 | 6.7 |
Account Receivables, % | 100 | 39.28 | 13.72 | 16.78 | 25.1 | 38.98 | 38.98 | 38.98 | 38.98 | 38.98 |
Inventories | .0 | 1.0 | -50.9 | .0 | .0 | .4 | .5 | .6 | .8 | .9 |
Inventories, % | 100 | 26.61 | -912.65 | 0 | 0 | 5.32 | 5.32 | 5.32 | 5.32 | 5.32 |
Accounts Payable | .4 | 1.0 | 2.7 | 4.1 | 4.6 | 4.4 | 5.2 | 6.2 | 7.4 | 8.9 |
Accounts Payable, % | 100 | 24.93 | 47.72 | 20.45 | 65.68 | 51.76 | 51.76 | 51.76 | 51.76 | 51.76 |
Capital Expenditure | -.9 | -.7 | -.9 | -.6 | -.8 | -.8 | -1.0 | -1.1 | -1.4 | -1.6 |
Capital Expenditure, % | 100 | -17.59 | -16.19 | -3.03 | -10.78 | -9.52 | -9.52 | -9.52 | -9.52 | -9.52 |
Tax Rate, % | -0.66914 | -0.66914 | -0.66914 | -0.66914 | -0.66914 | -0.66914 | -0.66914 | -0.66914 | -0.66914 | -0.66914 |
EBITAT | -10.0 | -15.5 | -43.3 | -33.0 | -43.8 | -5.1 | -6.0 | -7.2 | -8.6 | -10.3 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -10.6 | -17.8 | 10.6 | -85.2 | -41.1 | -5.8 | -4.2 | -5.0 | -6.0 | -7.1 |
WACC, % | 6.27 | 6.27 | 6.27 | 6.27 | 6.27 | 6.27 | 6.27 | 6.27 | 6.27 | 6.27 |
PV UFCF | ||||||||||
SUM PV UFCF | -23.3 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | -7 | |||||||||
Terminal Value | -171 | |||||||||
Present Terminal Value | -126 | |||||||||
Enterprise Value | -149 | |||||||||
Net Debt | -40 | |||||||||
Equity Value | -110 | |||||||||
Diluted Shares Outstanding, MM | 27 | |||||||||
Equity Value Per Share | -4.11 |
What You Will Get
- Real LAVA Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for LAVA Therapeutics N.V. (LVTX).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to suit your analysis.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on LAVA’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections specific to LAVA Therapeutics N.V. (LVTX).
- Time-Saving and Accurate: Skip building models from scratch while ensuring precision and flexibility in your assessments.
Key Features
- Customizable Research Parameters: Adjust essential inputs such as clinical trial success rates, market penetration, and R&D expenditures.
- Instant Valuation Metrics: Computes intrinsic value, net present value (NPV), and other key financial metrics in real-time.
- Industry-Leading Precision: Leverages LAVA Therapeutics’ actual financial data for accurate valuation results.
- Effortless Scenario Testing: Evaluate various assumptions and analyze different outcomes with ease.
- Efficiency Booster: Streamline your analysis process without the need to create intricate valuation models from the ground up.
How It Works
- Download: Obtain the pre-built Excel file containing LAVA Therapeutics N.V. (LVTX) financial data.
- Customize: Modify projections, such as revenue growth, EBITDA %, and WACC as needed.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various forecasts and assess outcomes immediately.
- Make Decisions: Leverage the valuation findings to inform your investment approach.
Why Choose This Calculator for LAVA Therapeutics (LVTX)?
- Accuracy: Utilizes real LAVA Therapeutics financial data to ensure precise calculations.
- Flexibility: Allows users to easily test and adjust inputs as needed.
- Time-Saving: Eliminates the need to create a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and detail expected by CFOs.
- User-Friendly: Intuitive design makes it accessible for users with varying levels of financial modeling experience.
Who Should Use This Product?
- Investors: Accurately assess LAVA Therapeutics N.V.'s (LVTX) fair value prior to making investment choices.
- CFOs: Utilize a high-quality DCF model for financial reporting and strategic analysis.
- Consultants: Easily customize the template for client valuation reports.
- Entrepreneurs: Acquire insights into the financial modeling practices of leading biotech firms.
- Educators: Employ it as a teaching resource to illustrate valuation techniques.
What the LAVA Template Contains
- Preloaded LVTX Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.